Reduction of connexin43 in human endothelial progenitor cells impairs the angiogenic potential

详细信息    查看全文

• 作者：Hsueh-Hsiao Wang (1) (2)
  Cheng-Huang Su (2) (3) (5)
  Yih-Jer Wu (1) (3)
  Jiun-Yi Li (4)
  Ya-Ming Tseng (1)
  Yi-Chun Lin (2)
  Chin-Ling Hsieh (2)
  Cheng-Ho Tsai (1) (3)
  Hung-I Yeh (1) (3)
  
• 关键词：Angiogenesis ; Connexin43 ; Connexins ; Endothelial progenitor cell
• 刊名：Angiogenesis
• 出版年：2013
• 出版时间：July 2013
• 年：2013
• 卷：16
• 期：3
• 页码：553-560
• 全文大小：727KB
• 参考文献：1. Tanaka K, Sata M (2007) Therapeutic application of bone marrow-derived progenitor cells for vascular diseases: magic bullets having the good without the bad? Int J Gerontol 1:10鈥?1 CrossRef
  2. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964鈥?67 CrossRef
  3. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Magner M, Isner JM (1999) Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 85:221鈥?28 CrossRef
  4. Urbich C, Dimmeler S (2004) Endothelial progenitor cells: characterization and role in vascular biology. Circ Res 95:343鈥?53 CrossRef
  5. Pathak AP, Hochfeld WE, Goodman SL, Pepper MS (2008) Circulating and imaging markers for angiogenesis. Angiogenesis 11:321鈥?35 CrossRef
  6. Bengel FM, Schachinger V, Dimmeler S (2005) Cell-based therapies and imaging in cardiology. Eur J Nucl Med Mol Imaging 32(Suppl 2):S404鈥揝416 CrossRef
  7. Galiano RD, Tepper OM, Pelo CR, Bhatt KA, Callaghan M, Bastidas N, Bunting S, Steinmetz HG, Gurtner GC (2004) Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells. Am J Pathol 164:1935鈥?947 CrossRef
  8. Dobaczewski M, Bujak M, Zymek P, Ren G, Entman ML, Frangogiannis NG (2006) Extracellular matrix remodeling in canine and mouse myocardial infarcts. Cell Tissue Res 324:475鈥?88 CrossRef
  9. Chou Y, Tsai CH, Ueng KC, Tian TY, Chen SC, Yeh HI (2007) Endothelial gap junctions are down-regulated by arsenic trioxide. Eur J Pharmacol 569:29鈥?6 CrossRef
  10. Bunderson M, Coffin JD, Beall HD (2002) Arsenic induces peroxynitrite generation and cyclooxygenase-2 protein expression in aortic endothelial cells: possible role in atherosclerosis. Toxicol Appl Pharmacol 184:11鈥?8 CrossRef
  11. Kumagai Y, Pi J (2004) Molecular basis for arsenic-induced alteration in nitric oxide production and oxidative stress: implication of endothelial dysfunction. Toxicol Appl Pharmacol 198:450鈥?57 CrossRef
  12. Xiao YF, Liu SX, Wu DD, Chen X, Ren LF (2006) Inhibitory effect of arsenic trioxide on angiogenesis and expression of vascular endothelial growth factor in gastric cancer. World J Gastroenterol 12:5780鈥?786
  13. Li JY, Su CH, Wu YJ, Tien TY, Hsieh CL, Chen CH, Tseng YM, Shi GY, Wu HL, Tsai CH, Lin FY, Yeh HI (2011) Therapeutic angiogenesis of human early endothelial progenitor cells is enhanced by thrombomodulin. Arterioscler Thromb Vasc Biol 31:2518鈥?525 CrossRef
  14. Wang HH, Lin CA, Lee CH, Lin YC, Tseng YM, Hsieh CL, Chen CH, Tsai CH, Hsieh CT, Shen JL, Chan WH, Chang WH, Yeh HI (2011) Fluorescent gold nanoclusters as a biocompatible marker for in vitro and in vivo tracking of endothelial cells. ACS Nano 5:4337鈥?344 CrossRef
  15. Wang HH, Kung CI, Tseng YY, Lin YC, Chen CH, Tsai CH, Yeh HI (2008) Activation of endothelial cells to pathological status by down-regulation of connexin43. Cardiovasc Res 79:509鈥?18 CrossRef
  16. Yeh HI, Lee PY, Su CH, Tian TY, Ko YS, Tsai CH (2006) Reduced expression of endothelial connexins 43 and 37 in hypertensive rats is rectified after 7-day carvedilol treatment. Am J Hypertens 19:129鈥?35 CrossRef
  17. Yeh HI, Lai YJ, Chang HM, Ko YS, Severs NJ, Tsai CH (2000) Multiple connexin expression in regenerating arterial endothelial gap junctions. Arterioscler Thromb Vasc Biol 20:1753鈥?762 CrossRef
  
• 作者单位：Hsueh-Hsiao Wang (1) (2)
  Cheng-Huang Su (2) (3) (5)
  Yih-Jer Wu (1) (3)
  Jiun-Yi Li (4)
  Ya-Ming Tseng (1)
  Yi-Chun Lin (2)
  Chin-Ling Hsieh (2)
  Cheng-Ho Tsai (1) (3)
  Hung-I Yeh (1) (3)
  
  1. Department of Medicine, Mackay Medical College, No. 46, Sec. 3, Zhongzheng Rd, Sanzhi District, New Taipei City, 252, Taiwan
  2. Department of Medical Research, Mackay Memorial Hospital, Taipei, Taiwan
  3. Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan
  5. Mackay Medicine, Nursing and Management College, Taipei, Taiwan
  4. Department of Surgery, Mackay Memorial Hospital, Taipei, Taiwan
  
• ISSN：1573-7209

文摘

Our previous work showed that arsenic trioxide down-regulated Cx43 and attenuated the angiogenic potential of human late endothelial progenitor cells (EPC). However, the relation between Cx43 and angiogenic activity of the EPC remained unclear. In the study, human late EPC were treated with siRNA specific to Cx43 (Cx43siRNA). The expression profiles as well as activity of the treated cells were examined. In parallel, the angiogenic potential of human EPC treated with Cx43siRNA was evaluated using murine hind limb ischemic model. The results showed that, in the EPC treated with Cx43siRNA, the activity of migration, proliferation, and angiogenic potential were attenuated, accompanied by reduction in vascular endothelial growth factor (VEGF) expression. In hind limb ischemia mice, EPC treated with Cx43siRNA lost the therapeutic angiogenic potential. VEGF supplementation partially recovered the activity impaired by Cx43 down-regulation. In conclusion, reduced Cx43 expression per se in the EPC causes decreased expression of VEGF and impaired angiogenic potential of the cells. Prevention of Cx43 reduction is a potential target to maintain the angiogenic potential of the EPC.